DK3966206T3 - Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf - Google Patents
Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK3966206T3 DK3966206T3 DK20728365.6T DK20728365T DK3966206T3 DK 3966206 T3 DK3966206 T3 DK 3966206T3 DK 20728365 T DK20728365 T DK 20728365T DK 3966206 T3 DK3966206 T3 DK 3966206T3
- Authority
- DK
- Denmark
- Prior art keywords
- heteroarylaminopyrimidinamide
- methods
- autophagy inhibitors
- autophagy
- inhibitors
- Prior art date
Links
- 239000012822 autophagy inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962846264P | 2019-05-10 | 2019-05-10 | |
US201962846260P | 2019-05-10 | 2019-05-10 | |
US201962911736P | 2019-10-07 | 2019-10-07 | |
US201962911733P | 2019-10-07 | 2019-10-07 | |
PCT/US2020/032090 WO2020231808A1 (en) | 2019-05-10 | 2020-05-08 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3966206T3 true DK3966206T3 (da) | 2023-11-13 |
Family
ID=70847594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK20728365.6T DK3966206T3 (da) | 2019-05-10 | 2020-05-08 | Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf |
Country Status (26)
Country | Link |
---|---|
US (2) | US11518758B2 (da) |
EP (2) | EP3966206B1 (da) |
JP (1) | JP2022531932A (da) |
KR (1) | KR20220019696A (da) |
CN (1) | CN114072397A (da) |
AU (2) | AU2020274011B2 (da) |
BR (1) | BR112021022576A2 (da) |
CA (1) | CA3139120A1 (da) |
CL (1) | CL2021002953A1 (da) |
CO (1) | CO2021016765A2 (da) |
DK (1) | DK3966206T3 (da) |
ES (1) | ES2962852T3 (da) |
FI (1) | FI3966206T3 (da) |
HR (1) | HRP20231310T1 (da) |
HU (1) | HUE064465T2 (da) |
IL (1) | IL287795A (da) |
LT (1) | LT3966206T (da) |
MX (1) | MX2021013662A (da) |
PE (1) | PE20220592A1 (da) |
PL (1) | PL3966206T3 (da) |
PT (1) | PT3966206T (da) |
RS (1) | RS64755B1 (da) |
SG (1) | SG11202112171XA (da) |
SI (1) | SI3966206T1 (da) |
TW (1) | TW202108574A (da) |
WO (1) | WO2020231808A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
EP3902547B1 (en) | 2018-12-28 | 2023-09-20 | Deciphera Pharmaceuticals, LLC | Csf1r inhibitors for use in treating cancer |
EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
EP4342469A3 (en) | 2019-05-10 | 2024-06-19 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
CN114072397A (zh) * | 2019-05-10 | 2022-02-18 | 德西费拉制药有限责任公司 | 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法 |
CN114258318B (zh) | 2019-06-17 | 2024-09-20 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12d阻害剤 |
WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
KR20230121758A (ko) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
CN113527294A (zh) * | 2021-08-25 | 2021-10-22 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
CN115894404B (zh) * | 2021-09-22 | 2024-07-16 | 杭州天玑济世生物科技有限公司 | 一类具有萘胺结构的小分子化合物及其应用 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024140401A1 (zh) * | 2022-12-30 | 2024-07-04 | 捷思英达控股有限公司 | 作为激酶抑制剂的杂环化合物以及包括其的组合物 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
AU783981C (en) | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
DE50212771D1 (de) | 2001-10-17 | 2008-10-23 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
JP4072615B2 (ja) | 2002-03-05 | 2008-04-09 | 独立行政法人産業技術総合研究所 | 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜 |
EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
ATE413404T1 (de) | 2003-07-16 | 2008-11-15 | Janssen Pharmaceutica Nv | Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3 |
PL1656372T3 (pl) | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym |
US20050113398A1 (en) | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
JP2008501698A (ja) | 2004-06-04 | 2008-01-24 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 代謝の調節因子としての置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する疾患の予防および処置 |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ, エルエルシー | 酵素モジュレータ及び治療 |
CN101137363B (zh) | 2005-01-07 | 2010-09-15 | 弗·哈夫曼-拉罗切有限公司 | 作为甘氨酸转运体1(GlyT-1)抑制剂用于治疗神经学和神经精神病学障碍的[4-(杂芳基)哌嗪-1-基]-(2,5-取代的-苯基)甲酮衍生物 |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
CA2641734A1 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
CA2650611A1 (en) | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
US20070293494A1 (en) | 2006-06-15 | 2007-12-20 | Djung Jane F | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
WO2008081928A1 (ja) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | ピラゾロピリミジン化合物 |
MX2009011343A (es) | 2007-04-20 | 2009-11-05 | Deciphera Pharmaceuticals Llc | Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas. |
JP2011500727A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
EP2303277A4 (en) | 2008-06-26 | 2011-08-17 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
EA201170627A1 (ru) | 2008-10-29 | 2011-10-31 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
MA33926B1 (fr) | 2009-12-17 | 2013-01-02 | Merck Sharp & Dohme | Aminopyrimidines en tant qu'inhibiteurs de la syk |
AU2010339456A1 (en) | 2009-12-30 | 2012-07-05 | Celgene Avilomics Research, Inc. | Ligand-directed covalent modification of protein |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
CA2800569A1 (en) | 2010-04-29 | 2011-11-03 | Deciphera Pharmaceuticals, Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities |
JPWO2012033195A1 (ja) | 2010-09-10 | 2014-01-20 | 京都薬品工業株式会社 | 複素環化合物 |
US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
JP2014521623A (ja) * | 2011-07-28 | 2014-08-28 | セルゾーム リミティッド | Jak阻害剤としてのヘテロシクリルピリミジンアナログ |
KR20140097402A (ko) | 2011-11-22 | 2014-08-06 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항증식 활성을 나타내는 피리돈 아미드 및 유사체 |
BR112014009717B1 (pt) | 2011-11-29 | 2022-06-14 | Genentech, Inc | Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica |
BR112014011850B1 (pt) | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
EP2785381B1 (en) | 2011-11-30 | 2016-05-18 | F.Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2017156493A1 (en) * | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
US9012635B2 (en) | 2013-03-15 | 2015-04-21 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9382228B2 (en) | 2013-03-15 | 2016-07-05 | Deciphera Pharmaceuticals, Llc | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
US9309224B2 (en) | 2013-03-15 | 2016-04-12 | Deciphera Pharmaceuticals, Llc. | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9181223B2 (en) | 2013-03-15 | 2015-11-10 | Deciphera Pharmaceuticals, Llc | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
CA2924362C (en) | 2013-09-18 | 2018-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of btk and/or jak3 kinases |
WO2015039613A1 (zh) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
JO3515B1 (ar) | 2013-10-18 | 2020-07-05 | Eisai R&D Man Co Ltd | مثبطات fgfr4 بيريميدين |
BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
US20150284341A1 (en) | 2014-04-07 | 2015-10-08 | Catylix, Inc. | Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine |
JP6684780B2 (ja) | 2014-08-25 | 2020-04-22 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 新規ulk1阻害剤およびそれを使用する方法 |
EP3262035A1 (en) | 2015-02-25 | 2018-01-03 | F. Hoffmann-La Roche AG | Alkynyl alcohols and methods of use |
WO2017023899A1 (en) | 2015-08-02 | 2017-02-09 | H. Lee Moffitt Cancer Center & Research Institute | Inhibitors of ack1/tnk2 tyrosine kinase |
WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
BR112019017741A2 (pt) | 2017-02-28 | 2020-04-07 | Dana Farber Cancer Inst Inc | usos de pirimidopirimidinonas como inibidores de sik |
WO2018222173A1 (en) | 2017-05-30 | 2018-12-06 | Deciphera Pharmaceuticals, Inc. | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
CN113214230B (zh) * | 2017-09-21 | 2022-10-04 | 北京赛特明强医药科技有限公司 | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 |
CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
AU2019251360A1 (en) | 2018-04-10 | 2020-10-08 | Neuropore Therapies, Inc. | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways |
EP3902547B1 (en) | 2018-12-28 | 2023-09-20 | Deciphera Pharmaceuticals, LLC | Csf1r inhibitors for use in treating cancer |
EP4342469A3 (en) | 2019-05-10 | 2024-06-19 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
CN114072397A (zh) * | 2019-05-10 | 2022-02-18 | 德西费拉制药有限责任公司 | 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法 |
CN114258318B (zh) | 2019-06-17 | 2024-09-20 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
-
2020
- 2020-05-08 CN CN202080049743.1A patent/CN114072397A/zh active Pending
- 2020-05-08 RS RS20230959A patent/RS64755B1/sr unknown
- 2020-05-08 TW TW109115472A patent/TW202108574A/zh unknown
- 2020-05-08 FI FIEP20728365.6T patent/FI3966206T3/fi active
- 2020-05-08 US US16/870,418 patent/US11518758B2/en active Active
- 2020-05-08 HU HUE20728365A patent/HUE064465T2/hu unknown
- 2020-05-08 EP EP20728365.6A patent/EP3966206B1/en active Active
- 2020-05-08 SI SI202030293T patent/SI3966206T1/sl unknown
- 2020-05-08 MX MX2021013662A patent/MX2021013662A/es unknown
- 2020-05-08 PE PE2021001871A patent/PE20220592A1/es unknown
- 2020-05-08 AU AU2020274011A patent/AU2020274011B2/en active Active
- 2020-05-08 DK DK20728365.6T patent/DK3966206T3/da active
- 2020-05-08 EP EP23190061.4A patent/EP4295846A3/en active Pending
- 2020-05-08 PT PT207283656T patent/PT3966206T/pt unknown
- 2020-05-08 KR KR1020217040561A patent/KR20220019696A/ko unknown
- 2020-05-08 HR HRP20231310TT patent/HRP20231310T1/hr unknown
- 2020-05-08 BR BR112021022576A patent/BR112021022576A2/pt unknown
- 2020-05-08 CA CA3139120A patent/CA3139120A1/en active Pending
- 2020-05-08 SG SG11202112171XA patent/SG11202112171XA/en unknown
- 2020-05-08 LT LTEPPCT/US2020/032090T patent/LT3966206T/lt unknown
- 2020-05-08 JP JP2021566466A patent/JP2022531932A/ja active Pending
- 2020-05-08 ES ES20728365T patent/ES2962852T3/es active Active
- 2020-05-08 PL PL20728365.6T patent/PL3966206T3/pl unknown
- 2020-05-08 WO PCT/US2020/032090 patent/WO2020231808A1/en active Application Filing
-
2021
- 2021-11-02 IL IL287795A patent/IL287795A/en unknown
- 2021-11-09 CL CL2021002953A patent/CL2021002953A1/es unknown
- 2021-12-10 CO CONC2021/0016765A patent/CO2021016765A2/es unknown
-
2022
- 2022-06-03 US US17/832,224 patent/US20230047915A1/en active Pending
-
2024
- 2024-05-14 AU AU2024203193A patent/AU2024203193A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20220592A1 (es) | 2022-04-22 |
IL287795A (en) | 2022-01-01 |
US20200354346A1 (en) | 2020-11-12 |
EP3966206A1 (en) | 2022-03-16 |
HUE064465T2 (hu) | 2024-04-28 |
TW202108574A (zh) | 2021-03-01 |
EP3966206B1 (en) | 2023-08-09 |
HRP20231310T1 (hr) | 2024-02-02 |
KR20220019696A (ko) | 2022-02-17 |
AU2020274011B2 (en) | 2024-02-15 |
PL3966206T3 (pl) | 2024-01-29 |
SI3966206T1 (sl) | 2023-12-29 |
SG11202112171XA (en) | 2021-12-30 |
AU2024203193A1 (en) | 2024-06-06 |
BR112021022576A2 (pt) | 2022-01-25 |
US20230047915A1 (en) | 2023-02-16 |
RS64755B1 (sr) | 2023-11-30 |
LT3966206T (lt) | 2023-11-10 |
CL2021002953A1 (es) | 2022-07-15 |
ES2962852T3 (es) | 2024-03-21 |
CO2021016765A2 (es) | 2022-04-08 |
FI3966206T3 (fi) | 2023-10-20 |
EP4295846A3 (en) | 2024-02-28 |
US11518758B2 (en) | 2022-12-06 |
WO2020231808A1 (en) | 2020-11-19 |
JP2022531932A (ja) | 2022-07-12 |
AU2020274011A1 (en) | 2021-11-25 |
PT3966206T (pt) | 2023-11-10 |
MX2021013662A (es) | 2022-03-11 |
EP4295846A2 (en) | 2023-12-27 |
CA3139120A1 (en) | 2020-11-19 |
CN114072397A (zh) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3966207T3 (da) | Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf | |
DK3966206T3 (da) | Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf | |
DK3788044T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf | |
DK3761980T3 (da) | Aminosyreforbindelser og fremgangsmåder til anvendelse | |
DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3559009T3 (da) | Sammensætninger og metoder til inhibition af arginaseaktivitet | |
DK3601358T5 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3788045T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf | |
DK3892628T3 (da) | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse | |
DK3618928T5 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3710430T3 (da) | Acss2-inhibitorer og fremgangsmåder til anvendelse deraf | |
DK4084778T3 (da) | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf | |
IL276711A (en) | Arginase inhibitors and methods of using them | |
DK3840837T3 (da) | Arginasehæmmere og fremgangsmåder til anvendelse deraf | |
IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
IL287973A (en) | acss2 inhibitors and methods of their use | |
DK3852533T3 (da) | Pyridazinoner og fremgangsmåder til anvendelse deraf | |
DK3743447T3 (da) | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf | |
DK4073098T3 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse | |
DK3630772T3 (da) | Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere | |
DK3743088T3 (da) | IL-22 Fc-sammensætninger og fremgangsmåder til anvendelse | |
DK3756455T3 (da) | Fremgangsmåde og anordning til fremstilling af krydderost | |
DK3710485T3 (da) | Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder | |
EP3793552C0 (en) | ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF | |
DK3921033T3 (da) | Arginasehæmmere og fremgangsmåder til anvendelse deraf |